MedTrace Logo

Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer

NCT05883670 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 118

Last updated 2023-06-01

No results posted yet for this study

Summary

This study is a Prospective, Multicenter, non-interventive Real-world Study to evaluate the efficacy and safety of the treatment of Serplulimab in patients with Advanced,Recurrent and Metastatic Cervical Cancer. Approximately 118 eligible subjects are planned to be enrolled across all sites.

Conditions

Interventions

DRUG

Serplulimab

Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Sponsors & Collaborators

  • Shandong University

    lead OTHER

Principal Investigators

  • Beihua Kong, MD.PhD. · Qilu Hospital of Shandong University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-09
Primary Completion
2024-03-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05883670 on ClinicalTrials.gov